Lung NeoplasmsSAFRO2202NCT07161882
ALG-LungCancerRegistry (SAFRO2202)
An observational study of Lung Neoplasms and Carcinoma, Non-Small-Cell Lung, run by Société Algérienne de Formation et de Recherche en Oncologie at 21 sites in Algeria.
Trial summary
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
- What is being tested?
- Observational Data Collection
- How many people
- 3,750 participants
- Where
- 21 sitesAlgeria
- Study dates
- 1 Jun 2025to Dec 2027
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors), recruited across 21 public or university hospitals in Algeria. Patients must have been diagnosed within 12 months prior to inclusion and be managed entirely within the public healthcare system.
Who may be able to join
- Age ≥ 18 years
- Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)
- Diagnosed at the time of inclusion or within the 12 previous months
- Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals
- Signed informed consent obtained
Who cannot join
- Prior enrollment in this study
- Participation in an interventional clinical trial
Trial locations and contacts
21 sites in 1 country. Contact the study team or a site near you to ask about taking part.
21 sites in 1 country
Algeria21 sites, 21 recruiting
- Recruiting
Centre Pierre et Marie Curie
Algiers, Algiers Province, 16000
Esma KERBOUA, MD, +213 770 86 81 10, esmakerboua@yahoo.fr
Esma KERBOUA, Professor of Medical Oncology
- Recruiting
Chu Beni Messous - Isaad Hassani
Algiers, Algiers Province, 16000
Merzak GHARNAOUT, MD, +213 561 27 06 89, mergharnaout@yahoo.fr
Merzak GHARNAOUT, Professor of Pulmonology
- Recruiting
CHU Mohamed Lamine Debaghine - Bab-el-Oued
Algiers, Algiers Province, 16000
Souad SOUILAH, MD, +213 550 39 62 70, souad.souilah@gmail.com
Souad SOUILAH, Professor of Pulmonology
- Recruiting
Chu-Beni Messous - Isaad Hassani
Algiers, Algiers Province, 16000
Mohammed OUKKAL, MD, +213 771 446 908, mohammedoukkal@gmail.com
Mohammed OUKKAL, Professor of Medical Oncology
- Recruiting
EPH Rouiba
Algiers, Algiers Province, 16000
Hassen MAHFOUF, MD, +213 550 59 40 60, mahfoufhassen@gmail.com
Hassen MAHFOUF, Professor of Medical Oncology
- Recruiting
CLCC Annaba
Annaba, Annaba, 23000
Hanène DJEDI, MD, +213 550 52 40 38, djedi_hanene@yahoo.fr
Hanène DJEDI, Professor of Medical Oncology
- Recruiting
CLCC Batna
Batna City, Batna
Wassila BENBRAHIM, MD, +213 663 373 369, w.khemilet@gmail.com
Wassila BENBRAHIM, Professor of Medical Oncology
- Recruiting
CHU- Hôpital Khelil Amrane
Béjaïa, Béjaia Province, 06000
Chahira MAZOUZI, MD, +213 553 68 20 71, shala_gouri@hotmail.com
Chahira MAZOUZI, Professor of Medical Oncology
- Recruiting
CAC-CHU Frantz Fanon
Blida, Blida Province
Adda BOUNEDJAR, MD, +213 661 651 010, a_bounedjar@yahoo.fr
Adda BOUNEDJAR, Professor of Medical Oncology
- Recruiting
CHU Dr Abdesselam Benbadis
Constantine, Constantine Province, 25000
Taha FILALI, MD, +213 671 69 60 75, tahafilali@gmail.com
Taha FILALI, Professor of Medical Oncology
- Recruiting
EH Didouche Mourad
Constantine, Constantine Province, 25000
Assia BENSALEM, MD, +213 661 51 44 88, assiabensalem@yahoo.fr
Assia BENSALEM, Professor of Medical Oncology
- Recruiting
CAC El OUED
El Oued, Oued Souf, 39000
Ahmed Zaki SADANI, MD, +213 771 446 908, time2@hotmail.fr
Ahmed Zaki SADANI, Professor of Medical Oncology
- Recruiting
CAC-Laghouat
Laghouat, Laghouat Province, 03000
Zakia Batoul BENLAHRECH, MD, +213 657 325 700, z.benlahrech@lagh-univ.dz
Zakia Batoul BENLAHRECH, Professor of Medical Oncology
- Recruiting
CAC Oran EL HASSI- EMIR ABDELKADER
Oran, Oran Province, 31000
Blaha LARBAOUI, MD, +213 560 33 02 01, larbaoui_onco@yahoo.fr
Blaha LARBAOUI, Professor of Medical Oncology
- Recruiting
CHU Dr. Benaouda Benzerdjeb
Oran, Oran Province, 31000
Abdelkader BOUSAHBA, MD, +213 559 85 56 93, aekbousahba@yahoo.fr
Abdelkader BOUSAHBA, Professor of Medical Oncology
- Recruiting
EHS 1er novembre
Oran, Oran Province, 31000
Faiza BEREKSI REGUIG, MD, +213 662 69 80 78, faizabereksireguig@yahoo.fr
Faiza BEREKSI REGUIG, Professor of Medical Oncology
- Recruiting
CAC- Ouargla
Ouargla, Ouargla Province, 30000
Hanina FIZI, MD, +213 775 18 23 50, haninaf@yahoo.fr
Hanina FIZI, Medical Oncologist
- Recruiting
CAC-Sétif
Sétif, Sétif Province, 19000
Hussein Adlane DIB, MD, +213 770 915 912, oncosetif@gmail.com
Hussein Adlane DIB, Professor of Medical Oncology
- Recruiting
CAC- Sidi Bel Abbès
Sidi Bel Abbes, Sidi Bel Abbès Province, 22000
Djamila YEKROU, MD, +213 549 79 11 28, djyekrou@yahoo.fr
Djamila YEKROU, Professor of Medical Oncology
- Recruiting
EPH- Sidi Ghiles
Tipasa, Sidi Ghiles, 42115
Fatma SEGHIER, MD, +213 540 464 853, seghierfatma@yahoo.fr
Fatma SEGHIER, Professor of Medical Oncology
- Recruiting
CLCC Draâ Ben Khedda
Tizi Ouzou, Draâ Ben Khedda, 15100
Cherifa SEDKAOUI, MD, +213 552 05 00 65, csedkaoui@yahoo.fr
Cherifa SEDKAOUI, Professor of Medical Oncology
About this study
Official title: Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.
Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.
Read more
The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).
The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.
Read the detailed description
Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide, and its incidence continues to rise in Algeria. Despite this increasing burden, real-world data regarding the epidemiology, clinical management, and treatment outcomes of lung cancer remain limited at the national level. The SAFRO 2202 ALG-Lung Cancer Registry was established to fill this gap by systematically collecting prospective, real-life data from a large sample of patients managed within Algeria's public healthcare system.
This study is a prospective, multicenter, non-interventional observational registry conducted across 21 hospital centers specialized in oncology and pulmonology. It includes adult patients (aged ≥18 years) with a confirmed diagnosis of lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. The study includes all patients diagnosed at the time of inclusion or within the 12 months preceding inclusion, provided they meet the eligibility criteria. All patients must be fully managed within the public healthcare system, including diagnosis, treatment, and follow-up.
Data will be collected as part of routine medical care, with no study-specific visits required, and will be entered into a secure electronic case report form (eCRF). Collected variables include demographic information, medical history, risk factors (especially smoking), tumor histology and molecular characteristics (e.g., EGFR, ALK, PD-L1, KRAS, ROS1, RET), ECOG performance status, and treatment modalities across different therapeutic lines.
The registry will also assess real-world treatment patterns and clinical outcomes, including objective response rate (based on RECIST 1.1), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). Adverse events and treatment-related toxicities will be documented and classified according to international standards (CTCAE). A minimum of 1,500 patients per year is expected, with at least 12 months of follow-up per patient.
This project aims to create a reliable national database to support health policy, optimize therapeutic strategies, and guide clinical research. By accounting for variations in clinical practices and patient profiles across the country, SAFRO 2202 is expected to generate robust evidence to improve lung cancer care in Algeria.
- Being tested
- Observational Data Collection
- Keywords
- Lung Cancer, Non-Small Cell Lung Cancer, Carcinoid Tumor, Treatment Outcomes, Drug-Related Side Effects, Registries, Algeria
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Carcinoid Tumor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational Data CollectionOther
Collection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study.
| Study group | Role | What they receive |
|---|---|---|
| Lung Cancer Patients Cohort | Adult patients (≥18 years) diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors) at the time of inclusion or within the previous 12 months, fully managed in oncology or pulmonology departments at one of the 21 participating public or university hospitals across Algeria. Data are collected prospectively during routine clinical care. Receives: Other: Observational Data Collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sociodemographic and clinical characteristics of lung cancer patients in Algeria
Patient age, sex, smoking history, comorbidities (e.g., COPD, diabetes, cardiovascular disease) and ECOG performance status, collected via eCRFs at inclusion in 21 oncology and pulmonology centers.
Measured: At baseline (inclusion)
Histological type and stage of lung cancer at diagnosis
Histological subtypes (NSCLC, SCLC, carcinoid tumors) and TNM stage of disease at diagnosis.
Measured: At baseline (diagnosis/inclusion)
Molecular profile of tumors
Frequency of molecular alterations (EGFR, ALK, KRAS, PD-L1, ROS1, RET, HER2, NTRK1, BRAF, MET, PIK3CA, MEK1) identified in tumor samples at diagnosis.
Measured: At baseline (inclusion)
First-line treatment modalities
Type of initial treatment received (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy).
Measured: At baseline (initiation of treatment)
Secondary outcomes (5)
Treatment-related toxicity according to CTCAE
Incidence, type, classification, severity, and impact of adverse events related to lung cancer treatments, assessed with CTCAE criteria.
Measured: From treatment initiation up to 12 months
Objective Response Rate (ORR)
Proportion of patients achieving complete or partial tumor response, assessed according to RECIST 1.1 criteria, based on real-world clinical and radiological data.
Measured: From treatment initiation up to 12 months
Progression-Free Survival (PFS)
Time from treatment initiation to first documented disease progression or death from any cause, whichever occurs first.
Measured: From treatment initiation up to 12 months
Time to Treatment Discontinuation (TTD)
Time from treatment initiation to discontinuation of therapy for any reason, including toxicity, disease progression, or patient/physician decision.
Measured: From treatment initiation up to 12 months
Overall Survival (OS)
Time from date of diagnosis to death from any cause, based on real-world clinical follow-up.
Measured: Minimum 12-month follow-up after diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2025
- Study start1 Jun 2025
- Primary completionJun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,750 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Société Algérienne de Formation et de Recherche en Oncologie
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca
- Responsible party
- Sponsor
- Investigators
- Adda BOUNEDJAR, Professor of Medical Oncology, Principal investigator, Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07161882
- Sponsor's protocol ID
- 013/SAF/OBS/EPD/2024
- Other IDs
- SAFRO 2202
- Acronym
- SAFRO2202
- Status last verified
- Aug 2025
- First submitted
- 25 Jun 2025
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The IPD will not be shared with external researchers. The data will be used exclusively by the study team for the purpose of scientific analysis and publication. No external access to individual-level data is planned.
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.
- ClinicalTrials.gov ID
- NCT07161882
- Acronym / sponsor ID
- SAFRO2202 / 013/SAF/OBS/EPD/2024
- Keywords
- Lung Cancer, Non-Small Cell Lung Cancer, Carcinoid Tumor, Treatment Outcomes, Drug-Related Side Effects, Registries, Algeria
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,750 participants (estimated)
- Lead sponsor
- Société Algérienne de Formation et de Recherche en OncologieUniversity, hospital or other
- Collaborators
- AstraZeneca
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 9 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.
Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.
The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).
The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.
Detailed description
Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide, and its incidence continues to rise in Algeria. Despite this increasing burden, real-world data regarding the epidemiology, clinical management, and treatment outcomes of lung cancer remain limited at the national level. The SAFRO 2202 ALG-Lung Cancer Registry was established to fill this gap by systematically collecting prospective, real-life data from a large sample of patients managed within Algeria's public healthcare system.
This study is a prospective, multicenter, non-interventional observational registry conducted across 21 hospital centers specialized in oncology and pulmonology. It includes adult patients (aged ≥18 years) with a confirmed diagnosis of lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. The study includes all patients diagnosed at the time of inclusion or within the 12 months preceding inclusion, provided they meet the eligibility criteria. All patients must be fully managed within the public healthcare system, including diagnosis, treatment, and follow-up.
Data will be collected as part of routine medical care, with no study-specific visits required, and will be entered into a secure electronic case report form (eCRF). Collected variables include demographic information, medical history, risk factors (especially smoking), tumor histology and molecular characteristics (e.g., EGFR, ALK, PD-L1, KRAS, ROS1, RET), ECOG performance status, and treatment modalities across different therapeutic lines.
The registry will also assess real-world treatment patterns and clinical outcomes, including objective response rate (based on RECIST 1.1), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). Adverse events and treatment-related toxicities will be documented and classified according to international standards (CTCAE). A minimum of 1,500 patients per year is expected, with at least 12 months of follow-up per patient.
This project aims to create a reliable national database to support health policy, optimize therapeutic strategies, and guide clinical research. By accounting for variations in clinical practices and patient profiles across the country, SAFRO 2202 is expected to generate robust evidence to improve lung cancer care in Algeria.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lung Cancer Patients Cohort | – | Other: Observational Data CollectionAdult patients (≥18 years) diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors) at the time of inclusion or within the previous 12 months, fully managed in oncology or pulmonology departments at one of the 21 participating public or university hospitals across Algeria. Data are collected prospectively during routine clinical care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors), recruited across 21 public or university hospitals in Algeria. Patients must have been diagnosed within 12 months prior to inclusion and be managed entirely within the public healthcare system.
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)
- Diagnosed at the time of inclusion or within the 12 previous months
- Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals
- Signed informed consent obtained
Key exclusion criteria (2 listed)
- Prior enrollment in this study
- Participation in an interventional clinical trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational Data CollectionCollection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study. | Other | Lung Cancer Patients Cohort |
Primary outcome
Sociodemographic and clinical characteristics of lung cancer patients in Algeria
Time frame: At baseline (inclusion)
Patient age, sex, smoking history, comorbidities (e.g., COPD, diabetes, cardiovascular disease) and ECOG performance status, collected via eCRFs at inclusion in 21 oncology and pulmonology centers.
Histological type and stage of lung cancer at diagnosis
Time frame: At baseline (diagnosis/inclusion)
Histological subtypes (NSCLC, SCLC, carcinoid tumors) and TNM stage of disease at diagnosis.
Molecular profile of tumors
Time frame: At baseline (inclusion)
Frequency of molecular alterations (EGFR, ALK, KRAS, PD-L1, ROS1, RET, HER2, NTRK1, BRAF, MET, PIK3CA, MEK1) identified in tumor samples at diagnosis.
First-line treatment modalities
Time frame: At baseline (initiation of treatment)
Type of initial treatment received (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy).
5 secondary outcomes
Treatment-related toxicity according to CTCAE
Time frame: From treatment initiation up to 12 months
Objective Response Rate (ORR)
Time frame: From treatment initiation up to 12 months
Progression-Free Survival (PFS)
Time frame: From treatment initiation up to 12 months
Time to Treatment Discontinuation (TTD)
Time frame: From treatment initiation up to 12 months
Overall Survival (OS)
Time frame: Minimum 12-month follow-up after diagnosis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Individual participant dataSharing planned: No. The IPD will not be shared with external researchers. The data will be used exclusively by the study team for the purpose of scientific analysis and publication. No external access to individual-level data is planned.
Related trials for Lung Neoplasms
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Adda BOUNEDJAR, Professor of Medical Oncology principal investigator
Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria
21 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Neoplasms and Carcinoma, Non-Small-Cell Lung, run by Société Algérienne de Formation et de Recherche en Oncologie at 21 sites in Algeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 21 sites in Algeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Louisa ISSIAKHEM LOUNICI, CEO (+213 770 48 43 36, l.issiakhem@cmsolutionsdz.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sociodemographic and clinical characteristics of lung cancer patients in Algeria (time frame: At baseline (inclusion)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.